PCSK9 Inhibitor improves outcomes for patients with peripheral artery disease

PCSK9 Inhibitor improves outcomes for patients with peripheral artery disease

By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Patients with peripheral artery disease (PAD) are at high risk of heart attack, stroke and cardiovascular death. In addition, PAD patients can suffer major adverse limb events, such as acute limb ischemia - the equivalent of a heart attack in the leg - that can lead to limb loss. Managing PAD is challenging for patients and physicians alike - despite best available treatment including high-intensity statins, risk of cardiovascular and limb events remains high. With few clinical trials focused on patients with PAD, physicians must often extrapolate from studies in broader populations with atherosclerosis about the best treatment approach for these patients. Unfortunately, few of these studies have characterized limb risk and fewer have demonstrated benefits of preventive therapies in reducing this risk. A new sub-analysis of the FOURIER clinical trial, however, now offers information on the safety and effectiveness of giving the PCSK9 inhibitor evolocumab on top of statin therapy to this high-risk population. At the 2017 American Heart Association Scientific Sessions, Marc Bonaca, MD, MPH, investigator at the TIMI Study Group and director of the Aortic Disease Center at Brigham and Women’s Hospital, …

https://www.newsrx.com/Butter/#!Search:a=14745537

(2017-12-02), PCSK9 Inhibitor improves outcomes for patients with peripheral artery disease, Obesity, Fitness & Wellness Week, 2195, ISSN: 1532-4664, BUTTER® ID: 014745537